Expression of serum exosomal miR‑23b‑3p in non‑small cell lung cancer and its diagnostic efficacy

  • Authors:
    • Jianping Wang
    • Hengchuan Xue
    • Zonghai Zhu
    • Jie Gao
    • Mengmeng Zhao
    • Zhenkai Ma
  • View Affiliations

  • Published online on: July 17, 2020     https://doi.org/10.3892/ol.2020.11891
  • Article Number: 30
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study aimed to investigate the expression of serum exosomal miR‑23b‑3p in non‑small cell lung cancer (NSCLC) and to determine its diagnostic efficacy for NSCLC. From October, 2017 to October, 2019, 80 patients with NSCLC, 60 patients with pneumonia and 30 healthy subjects undergoing physical examination were enrolled at the People's Hospital of Yangzhong City. Serum samples were collected from the 3 groups of patients. The expression of miR‑23b‑3p in exosomes was detected by RT‑qPCR. The Chi‑squared test was used to analyze the expression level of miR‑23b‑3p in exosomes, and the patients with NSCLC were divided into 2 groups according to the expression level. The association between the patient clinicopathological parameters and receiver operating characteristic (ROC) curves was used to evaluate the diagnostic efficacy of serum exosomal miR‑23b‑3p in NSCLC. The expression level of serum exosomal miR‑23b‑3p in the patients with NSCLC was significantly higher than that in patients with pneumonia (t=10.332, P<0.001) and healthy subjects (t=12.810, P<0.001); serum exosomal miR‑23b‑3p was significantly associated with tumor size, depth of invasion, liver metastasis and TNM stage (P<0.05). The area under the curve (AUC) for miR‑23b‑3p was 0.915 (95% CI, 0.84‑0.92), the optimal relative expression of miR‑23b‑3p was 3.46, the sensitivity of diagnosis was 87.4%, and the specificity was 93.8%, all higher than that of carcinoembryonic antigen (CEA). The ROCAUC of NSCLC was 0.645 (95% CI, 0.641‑0.772) and for Cyfra21‑1 it was 0.745 (95% CI, 0.701‑0.812). Compared with the patients with pneumonia and the healthy subjects, the patients with NSCLC exhibited a higher level of serum exosomal miR‑23b‑3p. On the whole, these findings indicate that miR‑23b‑3p has a higher clinical diagnostic efficacy and may thus be a potential biomarker for the early diagnosis of NSCLC.
View Figures
View References

Related Articles

Journal Cover

October-2020
Volume 20 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wang J, Xue H, Zhu Z, Gao J, Zhao M and Ma Z: Expression of serum exosomal miR‑23b‑3p in non‑small cell lung cancer and its diagnostic efficacy. Oncol Lett 20: 30, 2020.
APA
Wang, J., Xue, H., Zhu, Z., Gao, J., Zhao, M., & Ma, Z. (2020). Expression of serum exosomal miR‑23b‑3p in non‑small cell lung cancer and its diagnostic efficacy. Oncology Letters, 20, 30. https://doi.org/10.3892/ol.2020.11891
MLA
Wang, J., Xue, H., Zhu, Z., Gao, J., Zhao, M., Ma, Z."Expression of serum exosomal miR‑23b‑3p in non‑small cell lung cancer and its diagnostic efficacy". Oncology Letters 20.4 (2020): 30.
Chicago
Wang, J., Xue, H., Zhu, Z., Gao, J., Zhao, M., Ma, Z."Expression of serum exosomal miR‑23b‑3p in non‑small cell lung cancer and its diagnostic efficacy". Oncology Letters 20, no. 4 (2020): 30. https://doi.org/10.3892/ol.2020.11891